The in vitro activities of 16 cephalosporin derivatives and imipenem against 60 strains of Bordetella pertussis were examined. Cefoperazone, imipenem, and ceftriaxone were the most active, with MICs that inhibited 90% of the strains of 0.006, 0.05, and 0.1 ,Ig/ml, respectively. Cephalexin, cephradine, and cefsulodin were the least active, with MICs of 25 to 125 ,ug/ml. Gengou blood agar plates, using a multiple-replicator apparatus. Plates were used within 5 days of preparation except those containing unstable antibiotics, which were prepared fresh. They were incubated at 37°C in the dark for 42 to 45 h. Susceptibility was defined as the absence of visible growth at the point of inoculation. All strains were tested in duplicate. Sterility controls, drug-free solvent controls, growth controls, and control strains of Haemophilus influenzae and Pseudomonas aeruginosa with known MICs on BordetGengou medium were included in the assessments. MICs that inhibited 50 and 90% of the strains (MIC50 and MIC90)
The relative resistance of Bordetella pertussis over other respiratory flora to cephalexin has been made use of for many years in the formulation of selective isolation media (3, 5) . However, whether cephalexin is the ideal cephalosporin derivative for this purpose merits reevaluation in view of the recent proliferation of these compounds. Also, since several organisms resistant to the earlier cephalosporin derivatives are susceptible to the new ones (1) , a systenlatic examination of the in vitro activity of the new cephalosporin derivatives against B. pertussis could reveal potentially useful therapeutic agents.
Sixty separate clinical isolates of B. pertussis were tested against 16 cephalosporin derivatives and imipenem. Most strains had been passaged only a few times between isolation or lyophilization and testing. They were grown on BordetGengou medium for 3 days before inoculation into StainerScholte broth (4 Gengou blood agar plates, using a multiple-replicator apparatus. Plates were used within 5 days of preparation except those containing unstable antibiotics, which were prepared fresh. They were incubated at 37°C in the dark for 42 to 45 h. Susceptibility was defined as the absence of visible growth at the point of inoculation. All strains were tested in duplicate. Sterility controls, drug-free solvent controls, growth controls, and control strains of Haemophilus influenzae and Pseudomonas aeruginosa with known MICs on BordetGengou medium were included in the assessments. MICs that inhibited 50 and 90% of the strains (MIC50 and MIC90)
were calculated by the Reed and Muench method (2) .
The susceptibility of B. pertussis to the drugs tested, expressed in terms of inhibitory range, MIC50, and MIC90, are arranged in Table 1 . Cephalexin and the closely related cephradine were the least active (MICs of 125 and 100 ,ug/ml), and cefsulodin, the narrow-spectrum new cephalosporin derivative, was also only weakly active (MIC of 50.0 ,ug/ml). Cefoxitin, cefamandole, cefuroxime, cephalothin, ceftizoxime, cefazolin, cefaclor, and cephaloridine had MICs in the intermediately active range of 1 to 25 ,ug/ml. Only imipenem and the new cephalosporin derivatives cefotaxime, ceftazidime, ceftriaxone, and cefoperazone were active at concentrations below 1.0 ,ug/ml, and of these, cefoperazone appeared to be the most inhibitory (MIC of 0.012 jig/ml). During the screening of the early cephalosporin derivatives against B. pertussis for potentially useful therapeutic activity, the relative resistance of the organism was noted. This fact was made use of in the development of selective enrichment and isolation media (3, 5) . There are no records of the activity of later cephalosporin antibiotics in this regard. Also, in view of the expanded spectrums and more intense activities of the new cephalosporin derivatives and imipenem, a reexamination of the susceptibility status of the organism to these agents appears overdue.
The present study documents the susceptibility of 60 strains of B. pertussis to the early, late, and new agents. By and large, the isolates demonstrated either outright resistance or only limited susceptibility to the so-called firstgeneration drugs. Not unexpectedly, cephalexin and the closely related cephradine showed the weakest activity. The new cephalosporin derivative, cefsulodin, with its somewhat narrow spectrum, also demonstrated a high MIC. Since P. aeruginosa, which is susceptible to cefsulodin, is one of the few bacteria to regularly (though infrequently) break through the cephalexin barrier in standard isolation media, consideration might be given to the use of cefsulodin as an alternative selective agent. A number of agents showed levels of activity of limited use to bacteriologists and clinicians. But some of the newer derivatives exhibited inhibitory activities in the therapeutic range at levels comparable to those encountered against enteric gram-negative organisms or H. influenzae. In circumstances in which a parenteral agent is indicated for the antibiotic management of pertussis, drugs such as ceftriaxone and cefoperazone might merit some consideration.
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